| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 等值美元)OrbiMed Funds | 1,467,050 | 10.34% | 1.98% | 6 months |
| -OrbiMed Genesis | 969,900 | 6.84% | 1.31% | 6 months |
| -BIOG | 497,150 | 0.68% | 0.67% | 6 months |
| TruMed | 977,850 | 6.89% | 1.32% | 6 months |
| -TruMed Innovation Fund.. | 692,650 | 4.88% | 0.93% | 6 months |
| -TruMed Master Fund | 285,200 | 2.01% | 0.39% | 6 months |
| 华泰资本投资及其最终客户 | 1,630,050 | 11.48% | 2.20% | 6 months |
| -最终客户(高毅) | 978,050 | 1.34% | 1.32% | 6 months |
| -最终客户(睿郡) | 652,000 | 4.59% | 0.88% | 6 months |
| 睿远基金 | 815,050 | 5.75% | 1.09% | 6 months |
| -Vision Fund 1 | 474,650 | 3.34% | 0.64% | 6 months |
| -GSC Fund 1 | 258,900 | 1.83% | 0.35% | 6 months |
| -Horizon Fund 1 | 40,750 | 0.29% | 0.05% | 6 months |
| -Horizon Next Fund | 40,750 | 0.29% | 0.05% | 6 months |
| 富国 | 815,000 | 5.74% | 1.10% | 6 months |
| -富国基金 | 685,450 | 4.83% | 0.92% | 6 months |
| -富国香港 | 129,550 | 0.91% | 0.18% | 6 months |
| 惠理 | 651,900 | 4.59% | 0.88% | 6 months |
| -惠理基金管理香港有限公司 | 570,400 | 4.02% | 0.77% | 6 months |
| -惠理基金管理公司 | 81,500 | 0.57% | 0.11% | 6 months |
| GBAHIL | 407,500 | 0.56% | 0.55% | 6 months |
| FR M | 163,000 | 1.15% | 0.22% | 6 months |
| 源峰远景成长基金及中国银河国际投资(就源峰场外掉期而言) | 163,000 | 1.15% | 0.22% | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO garnered an overwhelming oversubscription ratio of 4762.58x, reflecting extreme market enthusiasm. The overall hit rate of just 10.53% underscores intense competition for allocations, typical of a hot biotech listing. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
甲尾 (A-tail) applicants with 50,000 lots received an expected 0.1785 lots, while 乙头 (B-head) applicants with 60,000 lots received a marginally higher 0.2401 lots. This narrow gap reveals an inefficient jump, as the additional 10,000 lots applied in B-tier yield only 0.0616 extra lots on average. (Broker fee structures vary and actual costs may differ. This analysis is for informational purposes only.)
Mainland China participants accounted for 61.8% of total holders, signaling strong cross-border demand for this biotech IPO. The investor base skewed slightly male at 58.9% with an average age of 42.4, typical for risk-tolerant growth sectors. (Data may contain errors or omissions; verify against official HKEX filings. Not financial advice.)
This page shows allotment analysis for Longbio-B (01779): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

